Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q3 2018 Earnings Presentation
8 slides from Angiodynamics's earnings presentation, Mar 29, 2018
Slide 1: Third Quarter 2018 Earnings Presentation
AngioDynamics Third Quarter 2018 Earnings Presentation March 29, 2018 ee
Slide 2: Forward-Looking Statement
2 Forward-Looking Statement Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Third Quarter 2018 Highlights
Third Quarter 2018 Highlights Financial Performance Revenue of $83.9 million, down 2.0% year over year (excluding the $1.7 million RFA sale in Japan from the prior year, sales were flat)Gross Margin ended at 54.2%, up 300 bps year over yearAdjusted EPS of $0.25, compared to $0.19 a year agoAdjusted
Slide 4: Third Quarter 2018 Results
Third Quarter 2018 Results FY2018 FY2017 FY2018 FY2017 $ in millions (except per share data) Q3 Results Q3 Results Change | YTD Results | YTD Results | Change Revenue $83.9 $85.6 (2.0)% $256.0 $262.7 (2.6)% - Peripheral Vascular 43.5 43.9 {0.8)% $149.8 $154.7 (3.2)% - Vascular Access 23.3 23.7 (1.7)
Slide 5: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation
Slide 6: Reconciliation of GAAP to Non-GAAP Gross Profit, Net Income and EPS
Reconciliation of GAAP to Non-GAAP Gross Profit, Net Income and EPS
Slide 7: Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS
Reconciliation of Net Income to EBITDAS to Adjusted EBITDAS
Slide 8: Growth through Focus, Execution, Accountability
Growth through Focus Execution Accountablity ee